MktsMarkets

Celldex Therapeutics, Inc.
NASDAQ: CLDXKey statistics
CLDX News
Stories mentioning CLDX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 15.00 | 730.00 | 695.00 | 1,175 | 3,191 | 2,498 | ||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | |||||||
| Operating Expenses | ||||||||
| Research & Development | 73,001 | 75,333 | 62,931 | 54,196 | 52,614 | 46,939 | 45,263 | 39,687 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (84,435) | (87,154) | (73,617) | (63,857) | (62,739) | (56,027) | (52,126) | (46,317) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (78,685) | (81,317) | (67,044) | (56,600) | (53,796) | (47,092) | (42,121) | (35,842) |
| Earnings Per Share (Basic) | (1.18) | (1.22) | (1.01) | (0.85) | (0.81) | (0.73) | (0.64) | (0.54) |
| Earnings Per Share (Diluted) | (1.18) | (1.22) | (1.01) | (0.85) | (0.81) | (0.73) | (0.64) | (0.54) |
| Weighted Average Shares Outstanding (Basic) | 66,566 | 66,422 | 66.00 | 66.00 | 66,383 | 64,395 | 66.00 | 66.00 |
| Weighted Average Shares Outstanding (Diluted) | 66,566 | 66,422 | 66.00 | 66.00 | 66,383 | 64,395 | 66.00 | 66.00 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About CLDX
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is a stock listed on the Nasdaq Stock Market under the ticker symbol CLDX. It last traded at $27.42 (Nov 20, 2026, 9:30 AM ET), down 1.9% on the day. That gives Celldex Therapeutics a market capitalisation of $2.2B.
Over the past 52 weeks CLDX has traded between $22.33 and $45.14.
Revenue for the quarter ended Mar 31, 2026 was $15.0K; a net loss of $78.7M. Revenue was down 97.8% from $695.0K in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $15.0K | -$78.7M | -524566.7% |
| Dec 31, 2025 | — | -$81.3M | — |
| Sep 30, 2025 | — | -$67.0M | — |
| Jun 30, 2025 | $730.0K | -$56.6M | -7753.4% |
From Celldex Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…